Floris H Groenendijk
Overview
Explore the profile of Floris H Groenendijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pham E, van den Berg C, Boere I, de Geus V, Haagsma J, Maliepaard M, et al.
Gynecol Oncol Rep
. 2025 Feb;
57:101679.
PMID: 39902376
Objective: This study aimed to assess the QoL in patients with uterine carcinosarcoma (UCS) and identify factors influencing survival. Methods: A prospective cohort study was conducted of patients with UCS...
2.
Pham E, van den Berg C, van Es R, van Doorn H, Groenendijk F, van Beekhuizen H
J Gynecol Oncol
. 2025 Jan;
PMID: 39853259
Objective: To determine the accuracy of aspiration biopsy (AB), hysteroscopic biopsy (HB), and dilatation & curettage (D&C) in detecting uterine carcinosarcoma (UCS). Methods: Pathology reports were retrieved from the Dutch...
3.
Zelisse H, van Gent M, Mom C, de Ridder S, Snijders M, Heeling M, et al.
Ann Diagn Pathol
. 2024 Nov;
74:152411.
PMID: 39591762
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago...
4.
Nowak-Sliwinska P, van Beijnum J, Griffioen C, Huinen Z, Sopesens N, Schulz R, et al.
Angiogenesis
. 2022 Dec;
26(2):279-293.
PMID: 36459240
Purpose: Ongoing angiogenesis renders the tumor endothelium unresponsive to inflammatory cytokines and interferes with adhesion of leukocytes, resulting in escape from immunity. This process is referred to as tumor endothelial...
5.
Zelisse H, van Gent M, de Ridder S, van der Aa M, Van Altena A, Bart J, et al.
Gynecol Obstet Invest
. 2022 Nov;
87(6):389-397.
PMID: 36450222
Objectives: Ovarian cancer has the worst overall survival rate of all gynecologic malignancies. For the majority of patients, the 5-year overall survival rate of less than 50% has hardly improved...
6.
Pruis M, Groenendijk F, Badloe K, van Puffelen A, Robbrecht D, Dinjens W, et al.
Br J Cancer
. 2022 May;
127(4):776-783.
PMID: 35606463
Background: Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients...
7.
Roepman P, de Bruijn E, van Lieshout S, Schoenmaker L, Boelens M, Dubbink H, et al.
J Mol Diagn
. 2021 May;
23(7):816-833.
PMID: 33964451
Whole genome sequencing (WGS) using fresh-frozen tissue and matched blood samples from cancer patients may become the most complete genetic tumor test. With the increasing availability of small biopsies and...
8.
Giang J, Biswas A, Mooyaart A, Groenendijk F, Dikrama P, Damman J
J Cutan Pathol
. 2020 Jul;
48(2):309-313.
PMID: 32623745
We present a case of trichoblastic carcinosarcoma with panfollicular differentiation. An 80-year-old man presented with a lesion on the left ear, which had been present for several months. Histopathology revealed...
9.
Vitale S, Groenendijk F, van Marion R, Beaufort C, Helmijr J, Dubbink H, et al.
Biomolecules
. 2020 Mar;
10(3).
PMID: 32156073
The aim of this study was to determine an optimal workflow to detect mutations in baseline and longitudinal serum cell free DNA (cfDNA) from high-grade serous ovarian carcinomas (HGSOC) patients...
10.
Mankor J, Paats M, Groenendijk F, Roepman P, Dinjens W, Dubbink H, et al.
Br J Cancer
. 2020 Feb;
122(7):953-956.
PMID: 32094484
Tumour mutational burden (TMB) has emerged as a promising biomarker to predict immune checkpoint inhibitors (ICIs) response in advanced solid cancers. However, harmonisation of TMB reporting by targeted gene panels...